Patents by Inventor Einat Amit Romach

Einat Amit Romach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
    Patent number: 10828308
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 10, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yaron Ilan, Doina Cosma Roman, Michael Hayden, Einat Amit-Romach
  • TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    Publication number: 20190000854
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: January 3, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    Publication number: 20170105996
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 20, 2017
    Applicants: Teva Pharmaceutical Industries, Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
    Publication number: 20170007596
    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Application
    Filed: June 7, 2016
    Publication date: January 12, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: David Silver, Einat Amit Romach
  • TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
    Publication number: 20160166565
    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 16, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: David Silver, Einat Amit Romach
  • TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
    Publication number: 20150037318
    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 5, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: David Silver, Einat Amit Romach